Adverse event | Drug(s) | Risk ratio | 95% CI | P value | Studies included | I2 % |
Depression | Dolutegravir | 0.86 | 0.56 to 1.33 | 0.51 | 1 | N/A |
Rilpivirine | 1.08 | 0.80 to 1.48 | 0.22 | 4 | 33 | |
Combined | 1.02 | 0.8 to 1.48 | 0.88 | 5 | 21 | |
Anxiety | Dolutegravir | 0.9 | 0.58 to 1.41 | 0.66 | 1 | N/A |
Rilpivirine | 0.68 | 0.35 to 1.34 | 0.27 | 3 | 75 | |
Combined | 0.75 | 0.48 to 1.18 | 0.21 | 4 | 64 | |
Insomnia | Dolutegravir | 1.07 | 0.38 to 2.99 | 0.89 | 2 | 45 |
Rilpivirine | 1 | 0.71 to 1.41 | 1 | 4 | 62 | |
Combined | 1.06 | 0.78 to 1.44 | 0.71 | 6 | 62 | |
Dizziness | Dolutegravir | 0.28 | 0.21 to 0.38 | <0.00001 | 2 | 0 |
Rilpivirine | 0.35 | 0.28 to 0.43 | <0.00001 | 5 | 0 | |
Combined | 0.33 | 0.28 to 0.39 | <0.00001 | 7 | 15.3 | |
Suicidal behaviour | Dolutegravir | 0.83 | 0.26 to 2.61 | 0.74 | 2 | 0 |
Rilpivirine | 1.32 | 0.36 to 4.8 | 0.67 | 3 | 17 | |
Combined | 1 | 0.45 to 2.22 | 0.6 | 5 | 0 |
N/A, not applicable; RCTs, randomised controlled trials.